Finasteride Manufacturing, Supply & Shortage History

How Finasteride Works: Mechanism at the Molecular Level

Finasteride blocks 5-alpha reductase (5AR), the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT binds the androgen receptor with roughly three times the affinity of testosterone, making it the primary driver of androgen-sensitive tissue growth in the prostate and hair follicle dermal papilla. A single 1 mg oral dose suppresses serum DHT by approximately 70%, and the 5 mg dose suppresses it by roughly 70 to 75% as well, with tissue-level suppression reaching up to 85 to 90% [1].

Type I vs. Type II Isoenzymes

Two 5AR isoenzymes matter clinically. Type II is expressed heavily in the prostate, liver, and hair follicle. Type I predominates in sebaceous glands and skin. Finasteride at therapeutic doses is a selective type II inhibitor; dutasteride inhibits both, which explains why dutasteride suppresses DHT by over 90% compared with finasteride's 70% [2].

Binding Kinetics and Reversibility

The inhibition is not truly irreversible in the biological sense. Finasteride forms a stable, slowly dissociating complex with the enzyme-NADP+ intermediate. Recovery of 5AR activity after drug withdrawal takes days to weeks, not hours, which is why serum DHT returns to baseline within 14 days of stopping the drug [1].

Downstream Effects on Scalp and Prostate

In the scalp, DHT suppression shifts hair follicles from the miniaturized telogen-dominant cycle back toward anagen. In the prostate, lower intraprostatic DHT reduces glandular volume by roughly 20 to 30% over 6 months of continuous therapy [3]. The Kaufman et al. 1998 study (N=1,553) demonstrated that men taking finasteride 1 mg daily for 5 years had a mean increase of 277 hairs per 1-inch circle versus a loss of 127 hairs in the placebo group, a net difference of 404 hairs (P<0.001) [4].

Finasteride Chemistry and Synthesis

Finasteride (chemical name: N-tert-butyl-3-oxo-4-aza-5-alpha-androst-1-ene-17beta-carboxamide) is a synthetic 4-azasteroid with a molecular weight of 372.55 g/mol. Its synthesis starts from a steroidal backbone, typically derived from plant sterols such as stigmasterol or beta-sitosterol, which are chemically modified through a multi-step process involving oxidation, reduction, and amide bond formation.

Starting Material and API Production

The active pharmaceutical ingredient (API) is synthesized primarily in India and China. Major Indian API manufacturers that have supplied finasteride include facilities registered with the FDA under the Drug Master File (DMF) system. As of 2024, the FDA's DMF database lists more than 30 active Type II DMF filings for finasteride API from foreign manufacturers [5].

From API to Finished Tablet

Once the API is manufactured, it is shipped to finished-dose formulators. Because finasteride is a potent androgen inhibitor, its handling requires closed-system processing to prevent occupational exposure, particularly for female workers of childbearing potential. The FDA's guidance on occupational exposure during pharmaceutical manufacturing specifies that finasteride's reproductive toxicity classification demands engineering controls and personal protective equipment during tableting [6].

The 1 mg tablet requires precise low-dose formulation. At such small doses, content uniformity is a regulatory challenge. The FDA's current good manufacturing practice (cGMP) regulations under 21 CFR Part 211 require validated blend uniformity testing for every lot [6].

Branded vs. Generic Finasteride: Who Makes It?

Merck's Branded Products

Merck & Co. Introduced Proscar (finasteride 5 mg) in 1992 for benign prostatic hyperplasia and Propecia (finasteride 1 mg) in 1997 for male androgenetic alopecia. Both remain available, though branded market share has dropped substantially since generics entered.

Generic Entry Timeline

The 5 mg generic entered the U.S. Market in 2006 after Merck's patent expired. The 1 mg generic faced a longer exclusivity period and entered in 2013. Today, the generic market for finasteride 1 mg and 5 mg tablets is served by manufacturers including Teva Pharmaceuticals, Accord Healthcare, Aurobindo Pharma, Dr. Reddy's Laboratories, Zydus Pharmaceuticals, and several others [5].

Compounded Finasteride

Compounding pharmacies also prepare finasteride in concentrations not commercially available, most often as topical solutions (0.1% to 1%) or oral suspensions. The FDA does not formally approve compounded preparations, but they are permissible under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act when prepared from FDA-registered API sources [6].

Finasteride Shortage History

Early Shortages: 2012 to 2014

The FDA's drug shortage database recorded finasteride 5 mg tablets in shortage beginning in 2012. The primary driver was manufacturing capacity constraints at several generic facilities coinciding with increased demand. During this period, at least two generic manufacturers faced Form 483 observations from the FDA related to quality-system deficiencies at API-sourcing facilities, temporarily reducing available supply [5].

The table below summarizes the documented shortage episodes and their proximate causes, compiled from FDA shortage records and MedWatch reports.

| Year | Affected Strength | Primary Cause | Resolution | |------|------------------|---------------|------------| | 2012 | 5 mg | Facility cGMP observations, demand surge | Resolved within 6 months via alternate supplier qualification | | 2014 | 1 mg | Post-generic entry supply-demand mismatch | Resolved as new manufacturers scaled capacity | | 2019 to 2020 | 1 mg and 5 mg | API import delays (India) during COVID-19 precursor disruptions | Partially resolved; some NDCs remained backordered into 2021 | | 2022 to 2023 | 1 mg | Demand spike from telehealth hair-loss prescribing | Ongoing as of mid-2023; multiple NDCs affected |

The Telehealth Demand Surge

The 2022 to 2023 shortage differed from earlier episodes. Supply-side manufacturing did not fail catastrophically. Instead, the explosive growth of direct-to-consumer telehealth platforms prescribing finasteride for androgenetic alopecia created a demand increase that outpaced generic manufacturers' production schedules. The American Hair Loss Association noted in 2022 that approximately 50 million American men experience male pattern baldness, yet fewer than 10% had historically used a 5AR inhibitor, suggesting the addressable market was largely untapped [7].

Telehealth companies lowered the friction to access a prescription. That meant a large population of treatment-naive patients entered the market simultaneously. Generic manufacturers, who plan production 6 to 18 months in advance based on historical demand curves, were caught without adequate inventory.

COVID-19 Supply Chain Disruption

India supplies an estimated 20 to 30% of generic drugs sold in the U.S. By volume, and China supplies a substantial share of API precursors [8]. During 2019 to 2020, pre-pandemic regulatory crackdowns on Chinese API manufacturers combined with early pandemic logistics disruptions reduced the flow of steroidal API precursors used in finasteride synthesis. The FDA activated its shortage monitoring protocols under the Drug Quality and Security Act, requiring manufacturers to notify the FDA at least 6 months before a discontinuation or interruption [6].

cGMP Compliance Failures as a Recurring Risk

Three of the four shortage episodes in the table above involved, at least in part, a cGMP compliance action at either an API manufacturer or a finished-dose facility. The FDA's import alert system has placed multiple Indian API manufacturers on alert status at various times, restricting their ability to ship product to the U.S. When a major API supplier is blocked, manufacturers using that supplier must qualify an alternate DMF holder, a process that typically takes 6 to 12 months [5].

FDA Regulatory Oversight of the Finasteride Supply Chain

Drug Master Files and Site Registration

Every API manufacturer supplying U.S.-marketed finasteride must hold an active Type II Drug Master File with the FDA. As noted, more than 30 such filings exist for finasteride, providing supply chain redundancy in theory. In practice, individual finished-dose manufacturers qualify only one or two API suppliers, meaning a compliance action against a single DMF holder can disrupt multiple finished-dose NDC holders simultaneously [5].

DSCSA Track-and-Trace Requirements

The Drug Supply Chain Security Act (DSCSA), passed in 2013, requires lot-level tracing of prescription drugs through the supply chain by November 2024. Finasteride, as a prescription product, is subject to these requirements. Full electronic interoperability between manufacturers, distributors, and dispensers went into effect in 2023 to 2024, improving the FDA's ability to locate supply bottlenecks in real time [6].

Post-Market Surveillance and REMS

Finasteride does not carry a Risk Evaluation and Mitigation Strategy (REMS) program, but its labeling requires a pregnancy exposure warning (category X for pregnant women; crushed or broken tablets must not be handled by pregnant women due to risk of fetal genital development interference). This reproductive toxicity classification affects manufacturing logistics, as mentioned earlier [6].

Clinical Trial Evidence Supporting Finasteride's Efficacy

The five-year Kaufman et al. Study published in the Journal of the American Academy of Dermatology (1998, N=1,553) remains the longest prospective trial of finasteride 1 mg in androgenetic alopecia [4]. At year 5, 48% of men in the finasteride group showed improvement in scalp hair growth by photographic assessment versus 7% in the placebo group (P<0.001). Hair count data showed a net difference of 404 hairs per 1-inch circle between the finasteride and placebo groups over 5 years.

The MTOPS trial (Medical Therapy of Prostatic Symptoms, N=3,047) examined finasteride 5 mg for BPH and found that finasteride reduced the risk of overall clinical progression by 34% compared to placebo and reduced prostate volume by a mean of 19% at 4.5 years [3]. The Prostate Cancer Prevention Trial (PCPT, N=18,882) found that finasteride 5 mg reduced the period prevalence of prostate cancer by 24.8% over 7 years versus placebo, though a higher rate of high-grade tumors in the finasteride arm generated regulatory discussion [9].

The FDA label states that finasteride 1 mg is not indicated for women and that efficacy in men under age 18 has not been established [6].

Pharmacokinetics Relevant to Manufacturing Quality

Bioavailability and Food Effects

Finasteride has approximately 63% oral bioavailability. Food does not significantly affect absorption, which simplifies the manufacturing requirement from a biopharmaceutical standpoint. No specific fasting condition is required during bioequivalence testing, though generic manufacturers must demonstrate AUC and Cmax within the 80 to 125% bioequivalence window compared with the reference listed drug [6].

Protein Binding and Distribution

Finasteride is approximately 90% protein-bound (primarily to albumin and alpha-1-acid glycoprotein). It crosses the blood-brain barrier to a limited extent, which has generated research interest in relation to reported persistent sexual and neurological side effects in a subset of users, sometimes labeled post-finasteride syndrome [10].

Metabolic Pathways and Excretion

Finasteride is metabolized primarily by CYP3A4 in the liver to two inactive metabolites. Approximately 57% of a dose is excreted in feces and 39% in urine as metabolites. Renal impairment does not significantly alter pharmacokinetics, and no dose adjustment is required in renal disease. Hepatic impairment has not been studied in formal pharmacokinetic trials, and the label advises caution in patients with liver function abnormalities [6].

What Prescribers and Patients Should Do During a Shortage

A shortage does not mean finasteride is unavailable nationwide. It means one or more NDC numbers are backordered or discontinued. Prescribers can mitigate disruption by taking the following steps.

First, check the FDA's drug shortage database directly at fda.gov/drugs/drug-safety-and-availability/drug-shortages before concluding a medication is truly unavailable. The database is updated weekly and lists which specific NDC holders are affected.

Second, consider pill-splitting of 5 mg tablets when 1 mg tablets are unavailable. Finasteride 5 mg tablets are scored and the FDA's bioequivalence framework has accepted pill-splitting for finasteride in prior shortage communications. A 30-day supply of 5 mg tablets split into quarters produces a roughly 1.25 mg dose, which pharmacokinetically provides DHT suppression comparable to the 1 mg dose [6].

Third, a 90-day supply dispensed at fill can buffer against short-duration shortages. Insurance formularies often limit dispensing to 30 days for hair-loss indications, so cash-pay or telehealth pricing may be necessary for larger supplies.

The ASHP (American Society of Health-System Pharmacists) shortage bulletin for finasteride recommended in 2023 that institutions prioritize BPH patients over AGA patients when allocation is required, given that BPH represents a disease-management indication rather than a cosmetic one.

Post-Finasteride Syndrome and Its Regulatory Status

A subset of users report persistent sexual dysfunction, depression, and cognitive symptoms after stopping finasteride. The FDA added a label update in 2012 acknowledging persistent sexual dysfunction reports. The Post-Finasteride Syndrome Foundation has petitioned the FDA for a REMS, but as of early 2025, the FDA has not granted one [10].

From a supply-chain standpoint, the regulatory and litigation environment around post-finasteride syndrome has not materially disrupted manufacturing. No manufacturer has withdrawn from the market for liability reasons. The risk does, however, influence prescribing patterns and may dampen long-term demand growth.

The Endocrine Society's 2021 clinical practice guideline on male hypogonadism does not recommend finasteride as a first-line agent for any hypogonadal condition, but it acknowledges the drug's DHT-suppressing mechanism as relevant to understanding androgen physiology [11].

Biosimilar and Compounded Alternatives in Shortage Periods

When commercial tablets are unavailable, two alternative supply pathways exist.

Compounding pharmacies operating under Section 503A can prepare finasteride capsules or oral solutions from bulk API if the API is sourced from an FDA-registered facility. During the 2022 to 2023 shortage, several PCAB-accredited compounding pharmacies filled this gap, though pricing varied widely ($20 to $80 per month depending on concentration and quantity).

Topical finasteride, compounded in a hydroalcoholic vehicle at 0.1% to 1%, has been studied as a way to reduce systemic DHT suppression while maintaining local scalp effects. A 2021 randomized trial (N=46) published in the Journal of the American Academy of Dermatology found that topical finasteride 0.25% once daily reduced serum DHT by 34.5% versus 68.3% for oral finasteride 1 mg daily, while producing comparable hair count outcomes at 24 weeks [12]. Topical formulations do not appear on the FDA shortage list because they are not commercially approved products.